| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 07/08/2004 | CA2551169A1 Organ preconditioning, arrest, protection preservation and recovery (2) |
| 07/08/2004 | CA2529816A1 Mixed esters of hyaluronic acid with retinoic and butyric acids |
| 07/08/2004 | CA2513086A1 Treatment of obesity and associated conditions with tgf-.beta. inhibitors |
| 07/08/2004 | CA2513077A1 Use of l-dopa, derivatives thereof and medicaments comprising said compounds for the prophylaxis of psychotic diseases |
| 07/08/2004 | CA2511726A1 Xanthine derivatives as muscarinic receptor antagonists |
| 07/08/2004 | CA2511360A1 Novel pharmaceuticals |
| 07/08/2004 | CA2511340A1 Pyrazolo[3,4-b]pyridine compounds, and their use as phosphodiesterase inhibitors |
| 07/08/2004 | CA2511208A1 Controlled release pharmaceutical compositions of tamsulosin |
| 07/08/2004 | CA2511202A1 Cyclopentil-substituted glutaramide compounds as endopeptidase inhibitors |
| 07/08/2004 | CA2511144A1 Ghrelin receptor inverse agonist for regulation of feeding behaviours |
| 07/08/2004 | CA2511142A1 Escitalopram hydrobromide and a method for the preparation thereof |
| 07/08/2004 | CA2510851A1 Benzoxazines and derivatives thereof as inhibitors of pi3ks |
| 07/08/2004 | CA2510850A1 2-(1h-indazol-6-ylamino)-benzamide compounds as protein kinases inhibitors useful for the treatment of ophthalmic diseases |
| 07/08/2004 | CA2510846A1 New carboxylic acid amides,the preparation thereof and their use as pharmaceutical compositions |
| 07/08/2004 | CA2510811A1 Use of substituted 2,5-diamidoindoles for the treatment of urological diseases |
| 07/08/2004 | CA2510780A1 Method of treating angiogenic tissue growth |
| 07/08/2004 | CA2510766A1 Use of prebiotics for preventing or treating oxidation stress |
| 07/08/2004 | CA2510711A1 Novel aminobenzophenone compounds |
| 07/08/2004 | CA2510465A1 Oral dosage forms with therapeutically active agents in controlled release cores and immediate release gelatin capsule coats |
| 07/08/2004 | CA2510458A1 Compositions of cholesteryl ester transfer protein inhibitors and hmg-coa reductase inhibitors |
| 07/08/2004 | CA2510445A1 Methods and compositions for the treatment of herpes virus infections using cyclooxygenase-2 selective inhibitors or cyclooxygenase-2 inhibitors in combination with antiviral agents |
| 07/08/2004 | CA2510069A1 The gene cluster involved in safracin biosynthesis and its uses for genetic engineering |
| 07/08/2004 | CA2510019A1 Process for preparing combination pharmaceutical formulations using supercritical fluids |
| 07/08/2004 | CA2509882A1 Silyl ethers |
| 07/08/2004 | CA2509688A1 Dosage forms comprising a cetp inhibitor and an hmg-coa reductase inhibitor |
| 07/08/2004 | CA2509645A1 Antibiotics containing borinic acid complexes and methods of use |
| 07/08/2004 | CA2509419A1 Macrolides |
| 07/08/2004 | CA2509403A1 Pyrazole compounds |
| 07/08/2004 | CA2509140A1 Complexes of e-2-methoxy-n-(3-{4-[3-methyl-4-(6-methyl-pyridin-3-yloxy)-phenylamino]-quinazolin-6-yl}-allyl)-acetamide, their method of production, and use |
| 07/08/2004 | CA2508851A1 Therapeutic agents |
| 07/08/2004 | CA2508840A1 Dosage forms comprising a cetp inhibitor and an hmg-coa reductase inhibitor |
| 07/08/2004 | CA2508657A1 Substituted 1-piperidin-4-yl-4-pyrrolidin-3-yl-piperazine derivatives and their use as neurokinin antagonists |
| 07/08/2004 | CA2508624A1 Novel piperidine derivatives as modulators of chemokine receptor ccr5 |
| 07/08/2004 | CA2508621A1 Adamantyl acetamides as 11-beta hydroxysteroid dehydrogenase inhibitors |
| 07/08/2004 | CA2508275A1 4-(1-(sulfonyl)-1h-indol-2-yl)-4-(hydroxy)-cyclohexa-2,5-dienone compounds and analogs thereof as therapeutic agents |
| 07/08/2004 | CA2508273A1 Disease treatment via antimicrobial peptide inhibitors |
| 07/08/2004 | CA2508269A1 Methods and dosage forms for reducing heart attacks in a hypertensive individual with a diuretic or a diuretic and an ace inhibitor combination |
| 07/08/2004 | CA2506627A1 Use of .alpha.-phenylthiocarboxylic and .alpha.-phenyloxycarboxylic acids with serum-glucose-lowering and serum-lipid-lowering activity |
| 07/08/2004 | CA2505599A1 Slow release formulation of clarithromycin |
| 07/08/2004 | CA2502138A1 Therapeutic applications of 2-substituted 4-heteroarylryrimidines |
| 07/07/2004 | EP1435359A1 A process for the purification of roxithromycin |
| 07/07/2004 | EP1435357A2 New process for the preparation of vinyl-pyrrolidinone cephalosporine derivatives |
| 07/07/2004 | EP1435353A1 Novel heterocyclic compound and anti-inflammatory agent |
| 07/07/2004 | EP1435352A2 9-[(Substituted glycyl)amido]-6-(substituted)-5-hydroxy-6-deoxytetracyclines |
| 07/07/2004 | EP1435244A1 Drugs ameliorating hypo-hdl cholesterolemia |
| 07/07/2004 | EP1435240A2 Solid oral dosage form comprising a combination of methformin and glibenclamide |
| 07/07/2004 | EP1435239A1 Stabilized and easily processable granule of amlodipine maleate |
| 07/07/2004 | EP1435238A1 Methods for treating apnea and apnea disorders using optically pure R (+) ondansetron |
| 07/07/2004 | EP1435237A1 Prevention of migraine recurrence |
| 07/07/2004 | EP1435236A1 Malignant cell differentiation inducer compositions and utilization of the same |
| 07/07/2004 | EP1435235A1 Use of hydroxyoleic acid and similar compounds in the production of medicaments |
| 07/07/2004 | EP1435234A1 Compositions for lessening oxidative stress |
| 07/07/2004 | EP1435232A1 Esters of L-carnitine or alkanoyl L-carnitines useful as cationic lipids for the intracellular delivery of pharmacologically active compounds |
| 07/07/2004 | EP1435231A1 Non-pegylated long-circulating liposomes |
| 07/07/2004 | EP1434991A2 New potent, selective and non toxic c-kit inhibitors |
| 07/07/2004 | EP1434990A2 Method for identifying compounds the specifically deplete mast cells |
| 07/07/2004 | EP1434885A2 21132, a human g-protein coupled receptor family member and uses therefor |
| 07/07/2004 | EP1434882A1 Aptamers containing sequences of nucleic acids or nucleic acid analogues bound homologously, or in novel complexes |
| 07/07/2004 | EP1434879A2 Hepatocellular carcinoma-related genes and polypeptides, and method for detecting hepatocellular carcinomas |
| 07/07/2004 | EP1434876A1 Expression profiling in the intact human heart |
| 07/07/2004 | EP1434794A2 Fragments of heat shock proteins and their use |
| 07/07/2004 | EP1434792A2 Peptidyl ketones as inhibitors of dpiv |
| 07/07/2004 | EP1434791A2 Specific binding agents of human angiopoietin-2 |
| 07/07/2004 | EP1434786A1 Androstane 17-beta-carboxamides as androgen receptor modulators |
| 07/07/2004 | EP1434782A2 2-propynyl adenosine analogs having a2a agonist activity and compositions thereof |
| 07/07/2004 | EP1434779A2 Cross-linked glycopeptide-cephalosporin antibiotics |
| 07/07/2004 | EP1434778A1 Cytotoxins, prodrugs, linkers and stabilizers useful therefor |
| 07/07/2004 | EP1434777A1 Benzisothiazolyl-substituted aminomethyl chromanes for treating diseases of the central nervous system |
| 07/07/2004 | EP1434775A1 3,4-di-substituted maleimide compounds as cxc-chemokine receptor antagonists |
| 07/07/2004 | EP1434774A1 3-(4-substituted heterocyclyl)-pyrrol-2-ylmethylidene)-2-indolinone derivatives as protein kinase inhibitors |
| 07/07/2004 | EP1434773A2 Heteroaryl substituted tetrazole modulators of metabotropic glutamate receptor-5 |
| 07/07/2004 | EP1434772A1 Compounds and methods |
| 07/07/2004 | EP1434769A2 Compounds useful as reversible inhibitors of cysteine proteases |
| 07/07/2004 | EP1434766A1 Piperidine compounds as muscarinic antagonists |
| 07/07/2004 | EP1434765A1 Substituted piperidines with selective binding to histamine h3-receptor |
| 07/07/2004 | EP1434763A2 Beta-lactamyl vasopressin v1a antagonists |
| 07/07/2004 | EP1434762A1 4'-methanesulfonyl-biphenyl derivatives as a highly selective cyclooxygenase-2 inhibitor |
| 07/07/2004 | EP1434761A1 Salts of guanidine derivatives and pharmaceutical preparations consisting thereof |
| 07/07/2004 | EP1434760A2 Carbonyloxy-cyanomethyl compounds as antiparasitic agents |
| 07/07/2004 | EP1434756A1 Novel compounds |
| 07/07/2004 | EP1434624A1 2-amino-6-(2,4,5-substituted-phenyl)-pyridines for use as nitric oxide synthase inhibitors |
| 07/07/2004 | EP1434603A2 Method of treatment using ligand-immunogen conjugates |
| 07/07/2004 | EP1434602A2 Cpg formulations and related methods |
| 07/07/2004 | EP1434598A2 Bestrophin and bestrophin homologous proteins involved in the regulation of energy homeostasis |
| 07/07/2004 | EP1434597A1 USE OF gp130 ACTIVATORS IN DIABETIC NEUROPATHY |
| 07/07/2004 | EP1434590A2 Method for inhibiting the formation of seromas using factor xiii |
| 07/07/2004 | EP1434589A2 Thioester-terminated water soluble polymers and method of modifying the n-terminus of a polypeptide therewith |
| 07/07/2004 | EP1434588A2 2-(amino-3,4-dioxo-1cyclobuten-1-yl)amino]alkyl]-acid derivatives for the treatment of pain |
| 07/07/2004 | EP1434587A1 Pharmaceutical combinations comprising salmeterol and fluticasone proprionate for the treatment of asthma |
| 07/07/2004 | EP1434586A1 Estrogen/gestagen combination preparation and application thereof |
| 07/07/2004 | EP1434585A1 Alkyne matrix metalloproteinase inhibitors |
| 07/07/2004 | EP1434584A2 Compositions and methods of treatment of cancer |
| 07/07/2004 | EP1434583A1 N-aroyl piperazine derivatives as orexin receptor antagonists |
| 07/07/2004 | EP1434582A2 Topical composition containing brucine and the use for the treatment of damaged mammalian skin |
| 07/07/2004 | EP1434581A1 3- hydroxy-(-4-trifluoromethylphenyl)-methyl-7-spirocyclobutyl-5,6,7,8-tetrahydroquinolin-5-ol derivatives and the use of the same as cholesterol ester transfer protein (cetp) inhibitors |
| 07/07/2004 | EP1434580A2 Allylamides useful in the treatment of alzheimer's disease |
| 07/07/2004 | EP1434579A1 Imidazole derivatives as antiinflammatory agents |
| 07/07/2004 | EP1434578A1 Arylsulphonyl-substituted tetrahydro- and hexahydro-carbazoles as 5-ht-6 receptor ligands |
| 07/07/2004 | EP1434577A1 Pyrrolidinone derivatives |
| 07/07/2004 | EP1434576A1 Method of alleviating pain |